Taiwan Biotech Co. Ltd.

Leadgene Biomedical, Inc. ("Leadgene Biomedical"), a leading innovator in recombinant proteins and antibodies, proudly announces the successful acquisition of Cytena Bioprocess Solutions. ("Cytena BPS"). This strategic move transforms the two companies from close strategic partners into key forces within a unified group, marking a significant milestone in advancing precision medicine and biotechnology innovation. Building on its acquisition of Leadgene SIDSCO earlier this year, Leadgene Biomedical will integrate Cytena BPS’s advanced capabilities into its robust technological platforms and resources. This integration aims to accelerate the development of early- and mid-stage innovative drugs, expand diagnostic reagent R&D, and enhance the company’s one-stop service industry chain. Cytena BPS, in parallel, has launched a brand revitalization initiative to position itself for global market opportunities. Driving Resilience Amid Global Supply Chain Restructuring In the face of global supply chain restructuring, Taiwan’s biotech companies are leveraging mergers and strategic alliances to strengthen industry chain resilience. According to the "2025 Taiwan Biotech M&A White Paper," comprehensive upstream and downstream integration has become a critical focus for mergers and acquisitions. Dr. Chasel Chuang, Chairman of Leadgene Biomedical, commented: "The addition of Cytena BPS not only fortifies our manufacturing supply chain but also represents a leap forward in advanced process capabilities. Together, we aim to drive competitive biotech innovations, enabling groundbreaking research to transition from the lab to clinical applications more efficiently." Expanding Capabilities Through Strategic Integration Following the acquisition of Leadgene SIDSCO earlier this year, Leadgene Biomedical has significantly enhanced its preclinical research and in-house validation capabilities for in vitro diagnostic (IVD) reagents and biological raw materials. With the addition of Cytena BPS, the company further deepens its expertise in advanced processes and automated cell line development. These two key integrations reflect a dual strategy of horizontal expansion and vertical integration, extending Leadgene’s one-stop service capabilities. A Vision for Global Impact and Future Growth Through these strategic moves, Leadgene Biomedical aims to showcase the value of "Taiwan-made" R&D on the global stage, contributing to the international biotechnology supply chain. These efforts also lay a solid foundation for the company’s future IPO plans, ensuring sustainable growth and innovation.